ArticleBioorganic & medicinal chemistry2025
Discovery of inhibitors of the cancer-promoting phosphatase PRL-3 and their evaluation in intestinal organoids.
Article in Bioorganic & medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Upregulation of the phosphatase of regenerating liver (PRL)-3 is associated with colorectal cancer as well as metastasis development and progression. PRL-3's overexpression impairs intestinal self-renewal capacity through causing intestinal stem cell death, correlating this cellular mechanism of tumor onset with PRL-3-mediated higher susceptibility to tumor formation upon inflammatory or mutational events. Therefore, PRL-3 inhibitors hold promise as potential therapeutic agents for cancer treatment. Based on the structure of the PRL inhibitor Analog 3, we evaluated here two sets of focused small molecule libraries and screened them in order to identify more potent and selective PRL-3 inhibitors. The best hit, named PRLthiophenib, showed higher inhibition potency in vitro than Analog 3 with improved selectivity for PRL-3 over other protein tyrosine phosphatases (PTPs), but not within the PRL family, which continues to be a challenge. PRLthiophenib presented high cellular stability and no long-term cytotoxicity. Furthermore, it rescued the growth capacity of an inducible PRL-3-expressing three-dimensional intestinal cell culture organoid system derived from a PRL-3 overexpressing mouse line, mimicking the rescue of intestinal self-renewal capacity. The results introduce PRLthiophenib as a complementary inhibitor to published ones and support drug discovery efforts toward therapeutic targeting of this challenging cancer-promoting phosphatase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.